TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companyβs Chairman and Chief Executive Officer, will participate in...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),Β today announced it ranked number one on the Deloitte Technology Fast 500β’, a ranking of the 500 fastest-growing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.33 | -9.9730458221 | 33.39 | 33.39 | 29.9 | 1782655 | 31.18434915 | CS |
4 | -3.965 | -11.6531961793 | 34.025 | 35.03 | 29.9 | 1949485 | 32.17521296 | CS |
12 | 8.23 | 37.7004122767 | 21.83 | 36.84 | 21.65 | 2878680 | 29.6189836 | CS |
26 | 11.562 | 62.5040544924 | 18.498 | 36.84 | 16.8901 | 3218140 | 25.31955355 | CS |
52 | 13.36 | 80 | 16.7 | 36.84 | 12.84 | 3502138 | 20.44503894 | CS |
156 | 10.93 | 57.1353894407 | 19.13 | 36.84 | 3.48 | 3860986 | 14.96819501 | CS |
260 | 19.24 | 177.818853974 | 10.82 | 56.74 | 3.48 | 3008664 | 17.85253969 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.